Biogen Idec Business Development Plan Includes Small Molecules For Oncology
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects the bulk of expenditures from a $200 mil. business development plan will go toward up-front milestones and new clinical costs for in-licensed drugs.
You may also be interested in...
Biogen Idec Agrees To Buy Syntonix
Biogen gains preclinical hemophilia B agent and novel delivery technology that could allow less frequent dosing.
Biogen Idec Agrees To Buy Syntonix
Biogen gains preclinical hemophilia B agent and novel delivery technology that could allow less frequent dosing.
Biogen Idec CEO James Mullen: An Interview With “The Pink Sheet” DAILY
Company is “open for business” on deals, Mullen says during break at Massachusetts Biotechnology Council investor conference.